Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic CancerHarshabad Singh, Andrew J. Aguirre, Rachel B. Keller et al.|Clinical Cancer Research|2023Cited by 46
Abstract B048: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302)Khurum Khan, T.R. Jeffry Evans, Uma Mukherjee et al.|Molecular Cancer Therapeutics|2023Cited by 1
Data from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic CancerHarshabad Singh, Andrew J. Aguirre, Rachel B. Keller et al.|Unknown|2023Cited by 0
Supplementary Table S10 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic CancerHarshabad Singh, Andrew J. Aguirre, Rachel B. Keller et al.|Unknown|2023Cited by 0
Supplementary Table S18 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic CancerHarshabad Singh, Andrew J. Aguirre, Rachel B. Keller et al.|Unknown|2023Cited by 0